{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:47:58Z","timestamp":1790326078538,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"am","delay-in-days":384,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.therap.2024.06.005","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T09:00:55Z","timestamp":1720947655000},"page":"279-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effets ind\u00e9sirables de l\u2019association tezacaftor\/ivacaftor\/elexacaftor pouvant mener \u00e0 un arr\u00eat de traitement\u00a0: \u00e0 propos d\u2019une s\u00e9rie de 10\u00a0cas"],"prefix":"10.1016","volume":"80","author":[{"given":"Elora","family":"Blaisonneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Le Dar\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Mercerolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Bacle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Triquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-No\u00eblle","family":"Osmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Belleguic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Polard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.06.005_bib0210","series-title":"The metabolic and molecular basis of inherited disease","first-page":"5121","article-title":"Cystic fibrosis","author":"Welsh","year":"2001"},{"key":"10.1016\/j.therap.2024.06.005_bib0215","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.therap.2024.06.005_bib0220","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","article-title":"Cystic fibrosis modulator therapies","volume":"74","author":"Jia","year":"2023","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.therap.2024.06.005_bib0225","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/14728214.2017.1418324","article-title":"An update on new and emerging therapies for cystic fibrosis","volume":"22","author":"Hudock","year":"2017","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.therap.2024.06.005_bib0230","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.therap.2024.06.005_bib0235","series-title":"Pharmacom\u00e9dicale.org. Modulateurs de CFTR","year":"2024"},{"key":"10.1016\/j.therap.2024.06.005_bib0240","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cells11111769","article-title":"CFTR modulators in people with cystic fibrosis: real-world evidence in France","volume":"11","author":"Regard","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.therap.2024.06.005_bib0245","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2024.06.005_bib0250","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2024.06.005_bib0255","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.201608-1754OC","article-title":"Lumacaftor\/ivacaftor in patients aged 6-11\u00a0years with cystic fibrosis and homozygous for F508del-CFTR","volume":"195","author":"Milla","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.therap.2024.06.005_bib0260","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2024.06.005_bib0265","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-2600(20)30510-5","article-title":"Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12\u00a0years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study","volume":"9","author":"Flume","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.therap.2024.06.005_bib0270","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3\u00a0trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2024.06.005_bib0275","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2024.06.005_bib0280","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3\u00a0open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6\u00a0through 11\u00a0years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.therap.2024.06.005_bib0285","doi-asserted-by":"crossref","first-page":"200051","DOI":"10.1183\/16000617.0051-2020","article-title":"Modulator treatment for people with cystic fibrosis: moving in the right direction","volume":"29","author":"Elborn","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.therap.2024.06.005_bib0290","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcf.2023.01.005","article-title":"Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: focus on Trikafta\u00ae\/Kaftrio\u00ae","volume":"22","author":"Purkayastha","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.therap.2024.06.005_bib0295","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2515\/therapie\/2011073","article-title":"R\u00e9actualisation de la m\u00e9thode fran\u00e7aise d\u2019imputabilit\u00e9 des effets ind\u00e9sirables des m\u00e9dicaments","volume":"66","author":"Arimone","year":"2011","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.06.005_bib0300","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jcf.2017.05.008","article-title":"Worsening anxiety and depression after initiation of lumacaftor\/ivacaftor combination therapy in adolescent females with cystic fibrosis","volume":"16","author":"McKinzie","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.therap.2024.06.005_bib0305","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.therap.2023.09.007","article-title":"Drug-induced psychiatric disorders: a pharmacovigilance update","volume":"79","author":"Montastruc","year":"2024","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.06.005_bib0310","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.psym.2017.04.001","article-title":"Cystic fibrosis transmembrane regulator modulators: implications for the management of depression and anxiety in cystic fibrosis","volume":"58","author":"Talwalkar","year":"2017","journal-title":"Psychosomatics"},{"key":"10.1016\/j.therap.2024.06.005_bib0315","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jad.2024.01.119","article-title":"Drug-induced depressive symptoms: an update through the WHO pharmacovigilance database","volume":"350","author":"Li","year":"2024","journal-title":"J Affect Disord"},{"key":"10.1016\/j.therap.2024.06.005_bib0320","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221144211","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on depression and anxiety in cystic fibrosis","volume":"16","author":"Zhang","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.therap.2024.06.005_bib0325","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of elexacaftor\/tezacaftor\/ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.therap.2024.06.005_bib0330","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.psym.2020.06.021","article-title":"Trikafta and psychopathology in cystic fibrosis: a case report","volume":"61","author":"Tindell","year":"2020","journal-title":"Psychosomatics"},{"key":"10.1016\/j.therap.2024.06.005_bib0335","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jcf.2023.05.005","article-title":"Characterization of sleep in emerging adults with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor","volume":"23","author":"Meltzer","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.therap.2024.06.005_bib0340","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"21","author":"Heo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.therap.2024.06.005_bib0345","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/phar.2710","article-title":"Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients","volume":"42","author":"Doligalski","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.therap.2024.06.005_bib0350","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Dagenais","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.therap.2024.06.005_bib0355","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(23)00247-3","article-title":"WS11.01\u00a0Challenging behaviours and mood changes in a large cohort of 6-11\u00a0year old children following elexacaftor\/tezacaftor\/ivacaftor initiation","volume":"22","author":"Lee","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.therap.2024.06.005_bib0360","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00127-2017","article-title":"The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites","volume":"4","author":"Schneider","year":"2018","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.therap.2024.06.005_bib0365","unstructured":"European Medicines Agency. KAFTRIO - R\u00e9sum\u00e9 des caract\u00e9ristiques du produit. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kaftrio-epar-product-information_fr.pdf [Consult\u00e9 le 28\u00a0juin 2024 (94\u00a0pp.)]."},{"key":"10.1016\/j.therap.2024.06.005_bib0370","series-title":"Acute Liver Failure in a Patient with Cystic Fibrosis Taking Triple Combination Modulator. TP35. TP035 Challenging Cases in Patients with Bronchiectasis","first-page":"198","author":"Sharma","year":"2021"},{"key":"10.1016\/j.therap.2024.06.005_bib0375","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0168-8278(90)90124-A","article-title":"Criteria of drug-induced liver disorders","volume":"11","author":"B\u00e9nichou","year":"1990","journal-title":"J Hepatol"},{"key":"10.1016\/j.therap.2024.06.005_bib0380","first-page":"S85","article-title":"P081\u00a0Adverse drug reactions linked to prolonged use of Kaftrio\u00ae","volume":"21","author":"Dooney","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.therap.2024.06.005_bib0385","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2021.05.017","article-title":"A case of self-limited drug induced liver injury under treatment with elexacaftor\/tezacaftor\/ivacaftor: when it is worth taking the risk","volume":"20","author":"Stylemans","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.therap.2024.06.005_bib0390","doi-asserted-by":"crossref","first-page":"S1161","DOI":"10.14309\/01.ajg.0000784684.45906.5d","article-title":"S2788\u00a0drug-induced liver injury from cystic fibrosis transmembrane conductance regulator (CFTR) modulators","volume":"116","author":"Le","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.therap.2024.06.005_bib0395","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.yrtph.2010.09.014","article-title":"The evaluation of drug rechallenge: the casopitant Phase III program","volume":"58","author":"Hunt","year":"2010","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.therap.2024.06.005_bib0400","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.29152","article-title":"Drug rechallenge following drug-induced liver injury","volume":"66","author":"Hunt","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.therap.2024.06.005_bib0405","series-title":"Evidence-based gastroenterology and hepatology","first-page":"208","article-title":"Drug-induced diarrhea","author":"Abraham","year":"2019"},{"key":"10.1016\/j.therap.2024.06.005_bib0205","unstructured":"European Medicines Agency. ORKAMBI. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/orkambi-epar-product-information_fr.pdf [Consult\u00e9 le 28\u00a0juin 2024 (108\u00a0pp.)]."}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724000738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724000738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T17:14:52Z","timestamp":1747761292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724000738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0040595724000738"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.06.005","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effets ind\u00e9sirables de l\u2019association tezacaftor\/ivacaftor\/elexacaftor pouvant mener \u00e0 un arr\u00eat de traitement\u00a0: \u00e0 propos d\u2019une s\u00e9rie de 10\u00a0cas","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}